Vaccines stop needing freezers. A patch stored in a cabinet at room temperature can be shipped anywhere.
At the intersection of materials science and global health equity, researchers from RMIT, MIT, and Harvard have charted a path toward mRNA vaccine patches that survive at room temperature — no freezers required. The fragile nanoparticles that carry genetic instructions into the body have long demanded cold chains that exclude the world's most vulnerable communities, and this work begins to dissolve that barrier. By watching particles behave through every stage of drying and rehydration, the team identified the design conditions that keep them intact, offering manufacturers a practical blueprint for vaccines that can travel where refrigeration cannot.
- Fourteen million children received no vaccines in 2024, and the cold chain — demanding temperatures as low as minus 70 degrees Celsius — is a central reason why.
- The mRNA-carrying nanoparticles inside dissolvable microneedle patches are structurally fragile, prone to collapse during the very drying process that makes room-temperature storage possible.
- Using advanced imaging and X-ray techniques, researchers watched particle behavior in real time, identifying two decisive variables: nanoparticle architecture and polymer concentration in the patch material.
- Get both factors right and the particles survive intact; get either wrong and biological activity is lost — a finding that gives manufacturers clear, actionable design targets.
- The research is now moving toward immune response testing and broader application to other mRNA medicines, with the full promise of the technology still ahead.
A collaboration spanning RMIT University, MIT, and Harvard Medical School has produced a detailed map of the conditions needed to keep mRNA vaccine patches stable at room temperature — a finding with profound implications for how vaccines reach the world's most isolated communities.
The challenge the team tackled is deceptively specific: the nanoparticles that ferry mRNA into the body are fragile, and the process of drying them into the dissolvable tips of a microneedle patch can destroy them. Most mRNA vaccines today require storage at extreme cold, sometimes below minus 70 degrees Celsius, a logistical demand that overwhelms health systems without reliable electricity or refrigeration. A patch that works at room temperature sidesteps that problem entirely.
To understand how to protect the particles, the researchers used advanced imaging and X-ray techniques to observe them at every stage — before drying, during, and after rehydration. The results pointed to two critical variables: the structural design of the nanoparticles themselves, and the concentration of polymer in the patch material. Both must be calibrated correctly for the particles to survive and retain their biological function.
Lead author Dr. Brendan Dyett described the work as a practical step toward distribution that is simpler and cheaper, while distinguished professor Calum Drummond framed it as foundational research aimed not at wealthy nations with robust infrastructure, but at the communities that have historically been left out.
The team's next steps include refining formulations, testing actual immune responses, and exploring whether the same principles can extend to other mRNA medicines. The direction is clear; the distance still to travel is real.
A team of researchers across three institutions has mapped out the conditions needed to keep mRNA vaccine patches stable at room temperature, a finding that could reshape how vaccines reach the world's most remote and under-resourced communities.
The work, published in Advanced Functional Materials, emerged from collaboration between RMIT University in Australia, MIT, and Harvard Medical School. The researchers focused on a specific challenge: the tiny nanoparticles that carry mRNA are fragile. When they're dried into the dissolvable material used in microneedle patches—those patches with hundreds of microscopic tips that deliver vaccine directly into skin—the particles can degrade. Understanding how to protect them through this drying and rehydration cycle was the puzzle the team set out to solve.
Why does this matter? Most mRNA vaccines today require storage in freezers, sometimes at temperatures below minus 70 degrees Celsius. That cold-chain requirement creates a logistical nightmare for countries without reliable electricity, refrigeration infrastructure, or the budget to maintain it. A vaccine patch that works at room temperature eliminates that barrier entirely. According to the World Health Organization and UNICEF, 14.3 million children globally received no vaccines at all in 2024. Cold-chain logistics is one reason why.
The researchers used advanced imaging and X-ray techniques to watch what happened to the mRNA-carrying particles at every stage: before drying, during the drying process, and after the patch was rehydrated. This allowed them to see which formulation conditions preserved the particles' structure and kept their biological activity intact. The findings revealed that two factors were critical: the design of the nanoparticles themselves and the amount of polymer used in the patch material. Get both right, and the particles survive the process. Get them wrong, and they fall apart.
Dr. Brendan Dyett, the lead author from RMIT, framed the work as a practical step toward distribution that is both easier and cheaper. "Many mRNA vaccines need to be stored at very low temperatures, adding cost and complexity to transport and delivery," he said. The study, he explained, helps clarify how the particles respond to drying and rehydration—essential knowledge for designing patches that are genuinely stable and practical to move around the world.
Calum Drummond, a distinguished professor at RMIT, positioned the research as foundational. The long-term goal, he said, is to support technologies that work not just in wealthy nations with robust cold chains, but in the places and communities that need them most. That's not rhetoric. It's the actual constraint that shapes vaccine access globally.
The team's next steps are to further refine the nanoparticle and patch formulations, test how the design translates into actual immune responses in the body, and explore whether the same approach could work for other mRNA medicines beyond vaccines. The pathway is becoming clearer, but the work is far from finished.
Citações Notáveis
Many mRNA vaccines need to be stored at very low temperatures, adding cost and complexity to transport and delivery. Our study helps explain how the particles that carry mRNA respond to drying and rehydration.— Dr. Brendan Dyett, RMIT University
The long-term goal is to support technologies that are not only effective, but practical for the places and communities that need them most.— Calum Drummond, RMIT Distinguished Professor
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that these particles are so fragile when dried?
Because the fragility is what's kept mRNA vaccines locked in freezers. If the particles break down during drying, the vaccine doesn't work. If you can't keep them intact, you can't make a room-temperature patch.
So the researchers watched them break down and figured out how to stop it?
Exactly. They used imaging to see what was happening at each stage—before, during, and after drying. That visibility let them identify which conditions protected the particles.
What were those conditions?
Two main things: how the nanoparticles themselves were designed, and how much polymer they mixed into the patch material. Both affect whether the particles survive the process intact.
And if this works, what changes?
Vaccines stop needing freezers. A patch stored in a cabinet at room temperature can be shipped anywhere—rural clinics, remote villages, places without electricity. That's the barrier that's kept 14 million children unvaccinated.
Is this ready to use now?
Not yet. They've shown it's possible in principle. Now they need to test whether the patches actually trigger immune responses, and whether the approach works for other mRNA medicines too.
How long until we see this in clinics?
That's the question no one can answer yet. The science is moving fast, but translating it into something people can actually use takes time.